Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 May;41(5):982–986. doi: 10.1128/aac.41.5.982

Pharmacokinetics of intramuscularly administered aminosidine in healthy subjects.

T P Kanyok 1, A D Killian 1, K A Rodvold 1, L H Danziger 1
PMCID: PMC163837  PMID: 9145856

Abstract

Aminosidine is an older, broad-spectrum aminoglycoside antibiotic that has been shown to be effective in in vitro and animal models against multiple-drug-resistant tuberculosis and the Mycobacterium avium complex. The objective of this randomized, parallel trial was to characterize the single-dose pharmacokinetics of aminosidine sulfate in healthy subjects (eight males, eight females). Sixteen adults (mean [+/- standard deviation] age, 27.6 +/- 5.6 years) were randomly allocated to receive a single, intramuscular aminosidine sulfate injection at a dose of 12 or 15 mg/kg of body weight. Serial plasma and urine samples were collected over a 24-h period and used to determine aminosidine concentrations by high-performance liquid chromatographic assay. A one-compartment model with first-order input, first-order output, and a lag time (Tlag) and with a weighting factor of 1/y2 best described the data. Compartmental and noncompartmental pharmacokinetic parameters were estimated with the microcomputer program WinNonlin. One subject was not included (15-mg/kg group) because of the lack of sampling time data. On average, subjects attained peak concentrations of 22.4 +/- 3.2 microg/ml at 1.34 +/- 0.45 h. All subjects had plasma aminosidine concentrations below 2 microg/ml at 12 h, and all but two subjects (one in each dosing group) had undetectable plasma aminosidine concentrations at 24 h. The dose-adjusted area under the concentration-time curve from 0 h to infinity of aminosidine was identical for the 12- and 15-mg/kg groups (9.29 +/- 1.5 versus 9.29 +/- 2.2 microg x h/ml per mg/kg; P = 0.998). Similarly, no significant differences (P > 0.05) were observed between dosing groups for peak aminosidine concentration in plasma, time to peak aminosidine concentration in plasma, Tlag, apparent clearance, renal clearance, elimination rate constant, and elimination half-life. A significant difference was observed for the volume of distribution (0.35 versus 0.41 liters/kg; P = 0.037) between the 12 and 15 mg/kg dosing groups. Now that comparable pharmacokinetic profiles between dosing groups have been demonstrated, therapeutic equivalency testing via in vitro pharmacokinetic and pharmacodynamic modelling and randomized clinical trials in humans should be conducted.

Full Text

The Full Text of this article is available as a PDF (312.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arcamone F., Bertazzoli C., Buogo A., Cassinelli G., Vigevani A. New studies in the field of aminoglycosidic aminocyclitol antibiotics. Panminerva Med. 1974 Jan-Feb;16(1-2):9–24. [PubMed] [Google Scholar]
  2. Bloch A. B., Cauthen G. M., Onorato I. M., Dansbury K. G., Kelly G. D., Driver C. R., Snider D. E., Jr Nationwide survey of drug-resistant tuberculosis in the United States. JAMA. 1994 Mar 2;271(9):665–671. [PubMed] [Google Scholar]
  3. Chunge C. N., Owate J., Pamba H. O., Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg. 1990 Mar-Apr;84(2):221–225. doi: 10.1016/0035-9203(90)90263-e. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  5. FISHER M. W., MANNING M. C., GAGLIARDI L. A., GAETZ M. R., ERLANDSON A. L. Paromomycin: experimental antibacterial activity. Antibiot Annu. 1959;7:293–303. [PubMed] [Google Scholar]
  6. Frieden T. R., Sterling T., Pablos-Mendez A., Kilburn J. O., Cauthen G. M., Dooley S. W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993 Feb 25;328(8):521–526. doi: 10.1056/NEJM199302253280801. [DOI] [PubMed] [Google Scholar]
  7. Goble M., Iseman M. D., Madsen L. A., Waite D., Ackerson L., Horsburgh C. R., Jr Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993 Feb 25;328(8):527–532. doi: 10.1056/NEJM199302253280802. [DOI] [PubMed] [Google Scholar]
  8. Jereb J. A., Kelly G. D., Dooley S. W., Jr, Cauthen G. M., Snider D. E., Jr Tuberculosis morbidity in the United States: final data, 1990. MMWR CDC Surveill Summ. 1991 Dec;40(3):23–27. [PubMed] [Google Scholar]
  9. Kanyok T. P., Reddy M. V., Chinnaswamy J., Danziger L. H., Gangadharam P. R. In vivo activity of paromomycin against susceptible and multidrug-resistant Mycobacterium tuberculosis and M. avium complex strains. Antimicrob Agents Chemother. 1994 Feb;38(2):170–173. doi: 10.1128/aac.38.2.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kayok T. P., Reddy M. V., Chinnaswamy J., Danziger L. H., Gangadharam P. R. Activity of aminosidine (paromomycin) for Mycobacterium tuberculosis and Mycobacterium avium. J Antimicrob Chemother. 1994 Feb;33(2):323–327. doi: 10.1093/jac/33.2.323. [DOI] [PubMed] [Google Scholar]
  11. Kirby W. M., Clarke J. T., Libke R. D., Regamey C. Clinical pharmacology of amikacin and kanamycin. J Infect Dis. 1976 Nov;134(Suppl):S312–S315. doi: 10.1093/infdis/135.supplement_2.s312. [DOI] [PubMed] [Google Scholar]
  12. Mariani B., Velluti G., Marchioni C. F. New therapeutic perspectives of aminosidine in pneumology. Bacteriological, physiopathological and clinical observations. Panminerva Med. 1974 Nov-Dec;16(11-12):376–390. [PubMed] [Google Scholar]
  13. Mendelson J., Portnoy J., Sigman H. Pharmacology of gentamicin in the biliary tract of humans. Antimicrob Agents Chemother. 1973 Nov;4(5):538–541. doi: 10.1128/aac.4.5.538. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Novarini A., Montanari A., Bruschi G., Rossi E., Borghetti A., Migone L. The kinetics of aminosidine in renal patients with different degrees of renal failure. Clin Nephrol. 1975 Jul;4(1):23–24. [PubMed] [Google Scholar]
  15. Pitt H. A., Roberts R. B., Johnson W. D., Jr Gentamicin levels in the human biliary tract. J Infect Dis. 1973 Mar;127(3):299–302. doi: 10.1093/infdis/127.3.299. [DOI] [PubMed] [Google Scholar]
  16. Schentag J. J., Jusko W. J. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther. 1977 Sep;22(3):364–370. doi: 10.1002/cpt1977223364. [DOI] [PubMed] [Google Scholar]
  17. Schentag J. J., Jusko W. J., Vance J. W., Cumbo T. J., Abrutyn E., DeLattre M., Gerbracht L. M. Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm. 1977 Dec;5(6):559–577. doi: 10.1007/BF01059684. [DOI] [PubMed] [Google Scholar]
  18. Scott J. A., Davidson R. N., Moody A. H., Grant H. R., Felmingham D., Scott G. M., Olliaro P., Bryceson A. D. Aminosidine (paromomycin) in the treatment of leishmaniasis imported into the United Kingdom. Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):617–619. doi: 10.1016/0035-9203(92)90151-2. [DOI] [PubMed] [Google Scholar]
  19. Seaman J., Pryce D., Sondorp H. E., Moody A., Bryceson A. D., Davidson R. N. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis. 1993 Sep;168(3):715–720. doi: 10.1093/infdis/168.3.715. [DOI] [PubMed] [Google Scholar]
  20. Telzak E. E., Sepkowitz K., Alpert P., Mannheimer S., Medard F., el-Sadr W., Blum S., Gagliardi A., Salomon N., Turett G. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med. 1995 Oct 5;333(14):907–911. doi: 10.1056/NEJM199510053331404. [DOI] [PubMed] [Google Scholar]
  21. Thakur C. P., Olliaro P., Gothoskar S., Bhowmick S., Choudhury B. K., Prasad S., Kumar M., Verma B. B. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):615–616. doi: 10.1016/0035-9203(92)90150-b. [DOI] [PubMed] [Google Scholar]
  22. Turett G. S., Telzak E. E., Torian L. V., Blum S., Alland D., Weisfuse I., Fazal B. A. Improved outcomes for patients with multidrug-resistant tuberculosis. Clin Infect Dis. 1995 Nov;21(5):1238–1244. doi: 10.1093/clinids/21.5.1238. [DOI] [PubMed] [Google Scholar]
  23. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm. 1978 Apr;6(2):165–175. doi: 10.1007/BF01117450. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES